{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T15:59:31Z","timestamp":1791388771867,"version":"4.3.3"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,8,10]],"date-time":"2023-08-10T00:00:00Z","timestamp":1691625600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Acquired reactive perforating collagenosis (ARPC) is a clinically challenging disease with an unclear pathogenesis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To evaluate the efficacy and safety of dupilumab for the treatment of ARPC, and analyze the expression of type 2 inflammation-related molecules in ARPC lesions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This retrospective cohort study included 20 patients with ARPC; 10 received dupilumab and 10 received conventional therapy. The efficacy and safety of dupilumab were evaluated at 12 weeks. Immunohistochemical and immunofluorescence analyses of T- and B-cell markers, and type 2 inflammation-related cytokines, were performed on skin samples from ARPC patients, atopic dermatitis (AD) patients, and healthy controls.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Significantly more patients showed improvements in the Investigator Global Assessment score (100% vs. 0%; p &amp;lt; 0.0001) and itching (90%\/8.33%, P =.001) in the dupilumab group compared to the conventional group at 12 weeks. There were no adverse effects in the dupilumab group. The ARPC lesions showed enhanced dermal infiltration of CD3+ T-cells, with a predominance of Th2 cells, similar to AD lesions. IL-4 and IL-13 were co-localized with GATA3 in ARPC lesions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Dupilumab improved ARPC charaterized with type 2 inflammation.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2023.1240262","type":"journal-article","created":{"date-parts":[[2023,8,10]],"date-time":"2023-08-10T22:51:15Z","timestamp":1691707875000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":24,"title":["Dupilumab improve acquired reactive perforating collagenosis characterized by type 2 inflammation"],"prefix":"10.3389","volume":"14","author":[{"given":"Ben","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yibei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruzeng","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,8,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2010.00918.x","article-title":"Acquired reactive perforating collagenosis: Current status","volume":"37","author":"Karpouzis","year":"2010","journal-title":"J Dermatol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(94)70065-6","article-title":"Acquired reactive perforating collagenosis. Report of six cases and review of the literature","volume":"30","author":"Faver","year":"1994","journal-title":"J Am Acad Dermatol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.15647","article-title":"Clinical practice guide for the treatment of perforating dermatosis","volume":"47","author":"Kawakami","year":"2020","journal-title":"J Dermatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2004.00978.x","article-title":"Reactive perforating collagenosis associated with scabies in a diabetic","volume":"18","author":"Brinkmeier","year":"2004","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1967.01610030055009","article-title":"Reactive perforating collagenosis","volume":"96","author":"Mehregan","year":"1967","journal-title":"Arch Dermatol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.1999.02722.x","article-title":"Acquired reactive perforating collagenosis associated with diabetes mellitus: eight cases that meet Faver\u2019s criteria","volume":"140","author":"Kawakami","year":"1999","journal-title":"Br J Dermatol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.1996.tb00094.x","article-title":"Reactive perforating collagenosis\u2013transepidermal elimination of type IV collagen","volume":"21","author":"Herzinger","year":"1996","journal-title":"Clin Exp Dermatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2001.03982.x","article-title":"Immunohistochemical analysis of transforming growth factor-beta3 expression in acquired reactive perforating collagenosis","volume":"144","author":"Kawakami","year":"2001","journal-title":"Br J Dermatol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.06.006","article-title":"Up-regulation of transforming growth factor-beta3 and extracellular matrix proteins in acquired reactive perforating collagenosis","volume":"60","author":"Gambichler","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1080\/10520295.2017.1312526","article-title":"Effects of IL-13 on TGF-\u03b2 and MMP-1 in periodontitis","volume":"92","author":"Beklen","year":"2017","journal-title":"Biotech Histochem"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14465","article-title":"Evaluation of clinicopathological and treatment characteristics of 80 patients with acquired perforating dermatosis","volume":"33","author":"Gore Karaali","year":"2020","journal-title":"Dermatol Ther"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/iid3.574","article-title":"Dupilumab may be an alternative option in the treatment of acquired reactive perforating collagenosis combined with AD","volume":"10","author":"Ying","year":"2022","journal-title":"Immun Inflammation Dis"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2022.08.013","article-title":"Dupilumab in acquired perforating dermatosis: A potential new treatment","volume":"28","author":"Alsebayel","year":"2022","journal-title":"JAAD Case Rep"},{"key":"B14","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1111\/ajd.13874","article-title":"Reactive perforating collagenosis successfully treated with dupilumab","volume":"63","author":"Gil-Lianes","year":"2022","journal-title":"Australas J Dermatol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15926","article-title":"Treatment of acquired reactive perforating collagenosis with dupilumab in a patient with end-stage renal disease","volume":"35","author":"Lee","year":"2022","journal-title":"Dermatol Ther"},{"key":"B16","doi-asserted-by":"publisher","first-page":"adv00401","DOI":"10.2340\/00015555-3701","article-title":"Investigator\u2019s global assessment of chronic prurigo: A new instrument for use in clinical trials","volume":"101","author":"Zeidler","year":"2021","journal-title":"Acta Derm Venereol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/bjd.18652","article-title":"Atopic dermatitis in the elderly: a review of clinical and pathophysiological hallmarks","volume":"182","author":"Williamson","year":"2020","journal-title":"Br J Dermatol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.anai.2020.05.028","article-title":"New and emerging treatments for inflammatory itch","volume":"126","author":"Erickson","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jaad.2020.03.049","article-title":"Dupilumab improves clinical manifestations, symptoms, and quality of life in adult patients with chronic nodular prurigo","volume":"83","author":"Chiricozzi","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14220","article-title":"Acquired perforating dermatosis: clinicopathological study of 31 cases, emphasizing pathogenesis and treatment","volume":"31","author":"Garc\u00eda-Malinis","year":"2017","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/ced.14851","article-title":"Acquired perforating dermatoses show increased levels of cutaneous advanced glycation end-products","volume":"47","author":"Bellinato","year":"2022","journal-title":"Clin Exp Dermatol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"a022236","DOI":"10.1101\/cshperspect.a022236","article-title":"Regulation of the immune response by TGF-\u03b2: from conception to autoimmunity and infection","volume":"9","author":"Sanjabi","year":"2017","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.jaad.2019.07.060","article-title":"Pathophysiologic mechanisms of itch in bullous pemphigoid","volume":"83","author":"Hashimoto","year":"2020","journal-title":"J Am Acad Dermatol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1240262\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,10]],"date-time":"2023-08-10T22:51:18Z","timestamp":1691707878000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1240262\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,10]]},"references-count":23,"alternative-id":["10.3389\/fimmu.2023.1240262"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1240262","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,10]]},"article-number":"1240262"}}